Biogen cost cuts drive profit beat, Alzheimer's drug sales jump

Biogen (BIIB.O) beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell.